-

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Enviva Inc. (EVA) Investors and Encourages Investors to Contact the Firm Before November 13, 2023

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Maryland on behalf of those who acquired Enviva Inc. (“Enviva” or the “Company”) (NYSE: EVA) securities during the period from November 3, 2022 through May 3, 2023 (the “Class Period”). Investors have until November 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

On May 3, 2023, Enviva unexpectedly revised down its 2023 guidance from a range of $305-335 million to $200-250 million and entirely eliminated its quarterly dividend payments. The Company stated that the decision to revise its capital allocation framework was implemented in order to preserve liquidity and a conservative leverage profile. Specifically, Enviva’s Chief Executive Officer Thomas Meth stated that the Company’s poor performance for the first quarter was due to operating cost overages and production challenges, such as unplanned repairs and maintenance expenses, professional fees, and customer mix impacting results. On this news, the price of Enviva shares declined by $14.34 per share, or approximately 67.2%, from $21.35 per share to close at $7.01 on May 4, 2023.

The lawsuit alleges that, throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material information about the financial condition of the Company including its (i) EBITDA and net loss forecasts; (ii) liquidity position; (iii) capital allocations; (iv) operation costs; (v) productivity; and (vi) the impact of these metrics on Enviva’s ability to continue paying dividends in 2023.

If you purchased or otherwise acquired Enviva securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:EVA

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

ALIGNMENT HEALTHCARE, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ:ALHC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 8, 2026, it was reported that a former executive at Alignment Healthcare fil...

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter (“CRL”) reg...

MELI INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving MercadoLibre, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of MercadoLibre, Inc, (“MercadoLibre” or the “Company”) (NASDAQ:MELI) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On May 7, 2026, MercadoLibre released its first quarter 2026 financial results and disclosed that loans which were...
Back to Newsroom